Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013

Hoon Young Suh1 Department of Clinical Pharmacology and Therapeutics, College of Medicine, Seoul National University Hospital, Seoul, Korea

Carl C Peck2 Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California, San Francisco, CA, USA

Kyung-Sang Yu1 Department of Clinical Pharmacology and Therapeutics, College of Medicine, Seoul National University Hospital, Seoul, Korea

Howard Lee1 Department of Clinical Pharmacology and Therapeutics, College of Medicine, Seoul National University Hospital, Seoul, Korea;3 Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KoreaCorrespondence[email protected]

Pages 4005-4016 | Published online: 08 Dec 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

IvySPSiuLLGarrett-MayerERubinsteinLApproaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committeeClin Cancer Res20101661726173620215542
PubMed Web of Science ®Google Scholar
US Food Drug AdministrationGuidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy VolunteersRockville, MDFood and Drug Administration2005 Available from: http://www.fda.gov/downloads/drugs/guidances/ucm078932.pdfAccessed July 6, 2005
Google Scholar
Committee for Medicinal Products for Human UseGuideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medical ProductsLondon, UKEuropean Medicines Agency2007 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdfAccessed July 19, 2007
Google Scholar
ReichertJMRosensweigCJFadenLBDewitzMCMonoclonal antibody successes in the clinicNat Biotech200523910731078
PubMed Web of Science ®Google Scholar
StebbingsRPooleSThorpeRSafety of biologics, lessons learnt from TGN1412Curr Opin Biotechnol200920667367719892543
PubMed Web of Science ®Google Scholar
SuntharalingamGPerryMRWardSCytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412N Engl J Med2006355101018102816908486
PubMed Web of Science ®Google Scholar
TibbittsJCavagnaroJAHallerCAMarafinoBAndrewsPASullivanJTPractical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticalsRegul Toxicol Pharmacol201058224325120558225
PubMed Web of Science ®Google Scholar
SharmaVMcNeillJHTo scale or not to scale: the principles of dose extrapolationB J Pharmacol20091576907921
PubMed Web of Science ®Google Scholar
Le TourneauCStathisAVidalLMooreMJSiuLLChoice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trialsJ Clin Oncol20102881401140720124167
PubMed Web of Science ®Google Scholar
ZouPYuYZhengNApplications of human pharmacokinetic prediction in first-in-human dose estimationAAPS J201214226228122407287
PubMed Web of Science ®Google Scholar
AgoramBMUse of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologicsBr J Clin Pharmacol200967215316019076987
PubMed Web of Science ®Google Scholar
HansenARCookNRicciMSChoice of starting dose for biopharmaceuticals in first-in-human phase I cancer clinical trialsOncologist201520665365925964306
PubMed Web of Science ®Google Scholar
TosiDLaghzaliYVinchesMClinical development strategies and outcomes in first-in-human trials of monoclonal antibodiesJ Clin Oncol201533192158216526014300
PubMed Web of Science ®Google Scholar
RosenLSHurwitzHIWongMKA phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancerClin Cancer Res201218174820482922767667
PubMed Web of Science ®Google Scholar
AgoramBMMartinSWvan der GraafPHThe role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modelling in translational research of biologicsDrug Discov Today200712231018102418061880
PubMed Web of Science ®Google Scholar
WangWWangEBalthasarJMonoclonal antibody pharmacokinetics and pharmacodynamicsClin Pharmacol Ther200884554855818784655
PubMed Web of Science ®Google Scholar
MiltonMNHorvathCJThe EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical developmentToxicol Pathol200937336337119246571
PubMed Web of Science ®Google Scholar
LowePJHijaziYLuttringerOYinHSarangapaniRHowardDOn the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug developmentXenobiotica20073710–111331135417968748
PubMed Web of Science ®Google Scholar
BokkersBGSlobWDeriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approachCrit Rev Toxicol200737535537317612951
PubMed Web of Science ®Google Scholar
ZhaoLRenT-hWangDDClinical pharmacology considerations in biologics developmentActa Pharmacol Sin201233111339134723001474
PubMed Web of Science ®Google Scholar
MullerPYMiltonMLloydPSimsJBrennanFRThe minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodiesCurr Opin Biotechnol200920672272919896825
PubMed Web of Science ®Google Scholar
EasterbrookPJGopalanRBerlinJMatthewsDRPublication bias in clinical researchLancet199133787468678721672966
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date